Nanoscope's MOGENRY Shows 4-Year Vision Gains in RP Trial
Dallas – September 18, 2026 -- Nanoscope Therapeutics will unveil four-year follow-up data showing sustained visual acuity gains from its gene therapy MOGENRY® in retinitis pigmentosa patients, with the FDA already having accepted and filed the company's Biologics License Application.
Christine Kay to present long-term durability data at Retina Society meeting
Dr. Christine Kay, Director of Clinical Research and Retinal Genetics at Vitreoretinal Associates in Gainesville, will present the data on September 23, 2026, at the 59th Annual Scientific Meeting of the Retina Society in Los Angeles. The presentation, titled "Lasting Vision Improvement With MCO-010 Optogenetic Therapy," draws on the REMAIN 4-year extension of the RESTORE Phase 2b/3 trial (NCT04945772) and is scheduled for 3:15 PM PT at the Fairmont Century Plaza Hotel.